{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lee LYW"],"funding":["Cancer Research UK","Blood Cancer UK","National Institute for Health Research (NIHR)"],"pagination":["188-196"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9936347"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(2)"],"pubmed_abstract":["<h4>Importance</h4>Accurate identification of patient groups with the lowest level of protection following COVID-19 vaccination is important to better target resources and interventions for the most vulnerable populations. It is not known whether SARS-CoV-2 antibody testing has clinical utility for high-risk groups, such as people with cancer.<h4>Objective</h4>To evaluate whether spike protein antibody vaccine response (COV-S) following COVID-19 vaccination is associated with the risk of SARS-CoV-2 breakthrough infection or hospitalization among patients with cancer.<h4>Design, setting, and participants</h4>This was a population-based cross-sectional study of patients with cancer from the UK as part of the National COVID Cancer Antibody Survey. Adults with a known or reported cancer diagno"],"journal":["JAMA oncology"],"pubmed_title":["Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional Evaluation."],"pmcid":["PMC9936347"],"funding_grant_id":["ACF-2019-02-010","28990","30195","CL-2018-02-002","CL-2018-18-002","ACF-2017-19-002","CL-2018-11-002","ACF-2020-02-006"],"pubmed_authors":["Middleton M","Clark J","Fowler T","Little M","Ghafoor Q","Williams ST","Cattell E","Shah K","Middleton G","Panneerselvam H","Sheehan R","Taylor H","Protheroe AS","Kinloch E","Patel G","Lydon A","Johal S","Rozmanowski S","Hattersley R","Murphy G","Grumett S","Patel V","Kahn R","Gerrand K","Starkey T","Ionescu MC","Potter V","McKenzie H","Ying Y","Iveson T","Bernhardt K","Rigg AS","Williams S","Al-Hajji Y","Lam E","Tuthill M","Rhodes M","Sintler M","Fittall MW","Johnson P","Buckley A","Swarup S","Lee AJX","Roux RL","Roques T","Harper-Wynne C","Cheng V","Benny L","Randle A","Platt JR","Eastlake L","Pascoe J","Lee SM","Beggs A","Robinson K","Tilby M","Lee LYW","Tillett T","Bytyci J","Appanna N","Tripathy A","UK COVID Cancer Programme","Robinson T","Watts I","Roylance R","Burnett A","Liu JKH","Barnard M","Khan S"],"additional_accession":[]},"is_claimable":false,"name":"Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional Evaluation.","description":"<h4>Importance</h4>Accurate identification of patient groups with the lowest level of protection following COVID-19 vaccination is important to better target resources and interventions for the most vulnerable populations. It is not known whether SARS-CoV-2 antibody testing has clinical utility for high-risk groups, such as people with cancer.<h4>Objective</h4>To evaluate whether spike protein antibody vaccine response (COV-S) following COVID-19 vaccination is associated with the risk of SARS-CoV-2 breakthrough infection or hospitalization among patients with cancer.<h4>Design, setting, and participants</h4>This was a population-based cross-sectional study of patients with cancer from the UK as part of the National COVID Cancer Antibody Survey. Adults with a known or reported cancer diagno","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-21T15:58:12.078Z","creation":"2024-11-08T09:16:36.826Z"},"accession":"S-EPMC9936347","cross_references":{"pubmed":["36547970"],"doi":["10.1001/jamaoncol.2022.5974"]}}